Goldman Sachs
FTXH icon

Goldman Sachs’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Goldman Sachs’s Portfolio FTXH Stock Details FTXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524K Sell
13,730
-5,624
-29% -$196K ﹤0.01% 5673
2026
Q1 		$665K Buy
19,354
+6,519
+51% +$223K ﹤0.01% 5395
2025
Q4 		$423K Sell
12,835
-18,867
-60% -$588K ﹤0.01% 5698
2025
Q3 		$904K Sell
31,702
-484
-2% -$13.2K ﹤0.01% 5088
2025
Q2 		$825K Buy
32,186
+12,714
+65% +$322K ﹤0.01% 4832
2025
Q1 		$535K Buy
19,472
+2,047
+12% +$56.7K ﹤0.01% 5144
2024
Q4 		$470K Sell
17,425
-30,417
-64% -$854K ﹤0.01% 5286
2024
Q3 		$1.38M Sell
47,842
-18,655
-28% -$534K ﹤0.01% 4419
2024
Q2 		$1.81M Buy
66,497
+21,933
+49% +$587K ﹤0.01% 3999
2024
Q1 		$1.25M Sell
44,564
-17,628
-28% -$485K ﹤0.01% 4199
2023
Q4 		$1.66M Buy
62,192
+26,703
+75% +$673K ﹤0.01% 4059
2023
Q3 		$907K Buy
35,489
+27,239
+330% +$720K ﹤0.01% 4331
2023
Q2 		$216K Buy
+8,250
New +$218K ﹤0.01% 5152
2023
Q1 		– Sell
-20,039
Closed -$550K – 6037
2022
Q4 		$550K Hold
20,039
– – ﹤0.01% 4816
2022
Q3 		$482K Hold
20,039
– – ﹤0.01% 5005
2022
Q2 		$530K Hold
20,039
– – ﹤0.01% 5038
2022
Q1 		$533K Hold
20,039
– – ﹤0.01% 5281
2021
Q4 		$542K Hold
20,039
– – ﹤0.01% 5315
2021
Q3 		$517K Hold
20,039
– – ﹤0.01% 5175
2021
Q2 		$519K Hold
20,039
– – ﹤0.01% 5192
2021
Q1 		$512K Buy
+20,039
New +$525K ﹤0.01% 5099

Other funds holding FTXH

LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
MIM
Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
NP
Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Goldman Sachs's FTXH Position: Q2 2026 in Review

Goldman Sachs reduced its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 29% in Q2 2026, selling an estimated $196K and leaving 13,730 shares worth $524K. The position accounts for ﹤0.01% of the portfolio, ranked #5673.

Goldman Sachs first reported a position in FTXH in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.81M in Q2 2024. 31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

  • Goldman Sachs held 13,730 shares of First Trust Nasdaq Pharmaceuticals ETF worth $524K as of Q2 2026.
  • Goldman Sachs sold 5,624 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $196K.
  • First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5673 holding.
  • Goldman Sachs first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2021 and has held it in 21 quarters since.
  • Goldman Sachs's First Trust Nasdaq Pharmaceuticals ETF position peaked at $1.81M in Q2 2024.
  • 31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.